1. Home
  2. PRLD vs NBB Comparison

PRLD vs NBB Comparison

Compare PRLD & NBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated

N/A

Current Price

$3.79

Market Cap

529.1M

Sector

Health Care

ML Signal

N/A

Logo Nuveen Taxable Municipal Income Fund of Beneficial Interest

NBB

Nuveen Taxable Municipal Income Fund of Beneficial Interest

N/A

Current Price

$14.30

Market Cap

456.2M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
PRLD
NBB
Founded
2016
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
529.1M
456.2M
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
PRLD
NBB
Price
$3.79
$14.30
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
★ $9.20
N/A
AVG Volume (30 Days)
★ 395.6K
72.5K
Earning Date
11-11-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 23.21
N/A
EPS
N/A
★ N/A
Revenue
★ $12,140,000.00
N/A
Revenue This Year
$258.83
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 73.43
N/A
52 Week Low
$1.15
$13.97
52 Week High
$6.83
$16.62

Technical Indicators

Market Signals
Indicator
PRLD
NBB
Relative Strength Index (RSI) 32.49 32.21
Support Level $3.40 N/A
Resistance Level $4.10 $15.97
Average True Range (ATR) 0.28 0.26
MACD -0.08 -0.05
Stochastic Oscillator 11.76 26.23

Price Performance

Historical Comparison
PRLD
NBB

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

About NBB Nuveen Taxable Municipal Income Fund of Beneficial Interest

Nuveen Taxable Municipal Income Fund is a closed-end fund incorporated in the United States. Its primary objective is current income through investments in taxable municipal securities; the secondary objective is to seek enhanced portfolio value and total return. The fund has single operating segment.

Share on Social Networks: